Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues

Yizhou Dong, Qian Shi, Huei Chen Pai, Chieh Yu Peng, Shiow Lin Pan, Che Ming Teng, Kyoko Nakagawa-Goto, Donglei Yu, Yi Nan Liu, Pei Chi Wu, Kenneth F. Bastow, Susan L. Morris-Natschke, Arnold Brossi, Jing Yu Lang, Jennifer L. Hsu, Mien Chie Hung, Eva Y.H.P. Lee, Kuo Hsiung Lee

研究成果: 雜誌貢獻文章同行評審

63 引文 斯高帕斯(Scopus)

摘要

Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure-activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19-21 and 24) exerted potent and selective antibreast cancer activity with IC50 values of 0.3,0.2,0.1, and 0.1 μg/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than 1 against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against a ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19-21 and 24 as clinical trial candidates is warranted.
原文英語
頁(從 - 到)2299-2308
頁數10
期刊Journal of Medicinal Chemistry
53
發行號5
DOIs
出版狀態已發佈 - 三月 11 2010
對外發佈

ASJC Scopus subject areas

  • 分子醫學
  • 藥物發現

指紋

深入研究「Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues」主題。共同形成了獨特的指紋。

引用此